Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials

References

• Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369-75
   PubMed Web of Science ®Google Scholar
• Lee JW, Shahzad MM, Lin YG, et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009;15:2695-702
   Google Scholar
• Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44
   PubMed Web of Science ®Google Scholar
• Guo K, Ma Q, Wang L, et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009;22:825-30
   PubMed Web of Science ®Google Scholar
• Schuller HM, Porter B, Riechert A. Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J Cancer Res Clin Oncol 2000;126:624-30
   PubMed Web of Science ®Google Scholar
• Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010;70:7042-52
   PubMed Web of Science ®Google Scholar
• Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006;118:2744-9
   PubMed Web of Science ®Google Scholar
• Masur K, Niggemann B, Zanker KS, et al. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001;61:2866-9
   PubMed Web of Science ®Google Scholar
• Fitzgerald PJ. Is norepinephrine an etiological factor in some types of cancer? Int J Cancer 2009;124:257-63
   PubMed Web of Science ®Google Scholar
• Entschladen F, Drell TL 4th, Lang K, et al. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 2004;5:254-8
   PubMed Web of Science ®Google Scholar
• Drell TL 4th, Joseph J, Lang K, et al. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003;80:63-70
   PubMed Web of Science ®Google Scholar
• Lin X, Luo K, Lv Z, et al. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. Hepatogastroenterology 2012;59:584-8
   PubMed Web of Science ®Google Scholar
• Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003;9:4514-21
   PubMed Web of Science ®Google Scholar
• Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006;66:10357-64
   PubMed Web of Science ®Google Scholar
• Yang EV, Kim SJ, Donovan EL, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009;23:267-75
   PubMed Web of Science ®Google Scholar
• Chakroborty D, Sarkar C, Basu B, et al. Catecholamines regulate tumor angiogenesis. Cancer Res 2009;69:3727-30
   PubMed Web of Science ®Google Scholar
• Park SY, Kang JH, Jeong KJ, et al. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism. Int J Cancer 2011;128:2306-16
   PubMed Web of Science ®Google Scholar
• Entschladen F, Drell TL 4th, Lang K, et al. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005;11:403-11
   PubMed Web of Science ®Google Scholar
• Chalothorn D, Zhang H, Clayton JA, et al. Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia. Am J Physiol Heart Circ Physiol 2005;289:H947-59
   Google Scholar
• Liao X, Che X, Zhao W, et al. The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol Rep 2010;24:1669-76
   PubMed Web of Science ®Google Scholar
• Zhang D, Ma Q, Shen S, et al. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist’s anticancer effect in pancreatic cancer cell. Pancreas 2009;38:94-100
   PubMed Web of Science ®Google Scholar
• Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009;20:477-82
   PubMed Web of Science ®Google Scholar
• Powe DG, Voss MJ, Zänker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1:628-38
   PubMed Web of Science ®Google Scholar
• Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 2012;127:375-8
   PubMed Web of Science ®Google Scholar
• Grytli HH, Fagerland MW, Fosså SD, et al. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 2013;73(3):250-60. published online 20 July 2012, doi:10.1002/pros.22564
   Google Scholar
• De Giorgi V, Grazzini M, Gandini S, et al. Treatment with {beta}-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011;171:779-81
   PubMed Web of Science ®Google Scholar
• Lemeshow S, Sørensen HT, Phillips G, et al. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011;20:2273-9
   PubMed Web of Science ®Google Scholar
• Shah SM, Carey IM, Owen CG, et al. Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011;72:157-61
   PubMed Web of Science ®Google Scholar
• Algazi M, Plu-Bureau G, Flahault A, et al. Could treatments with beta-blockers be associated with a reduction in cancer risk? Rev Epidemiol Sante Publique 2004;52:53-65
   PubMed Web of Science ®Google Scholar
• Perron L, Bairati I, Harel F, et al. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004;15:535-41
   PubMed Web of Science ®Google Scholar
• Nkontchou G, Aout M, Mahmoudi A, et al. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila) 2012;5:1007-14
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011;29:2635-44
   PubMed Web of Science ®Google Scholar
• Ganz PA, Habel LA, Weltzien EK, et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011;129:549-56
   PubMed Web of Science ®Google Scholar
• Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011;29:2645-52
   PubMed Web of Science ®Google Scholar
• Friedman GD, Udaltsova N, Chan J, et al. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control 2009;20:1821-35
   PubMed Web of Science ®Google Scholar
• Fryzek JP, Poulsen AH, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006;97:231-6
   PubMed Web of Science ®Google Scholar
• Jansen L, Below J, Chang-Claude J, et al. Beta blocker use and colorectal cancer risk: population-based case–control study. Cancer 2012;118:3911-19
   PubMed Web of Science ®Google Scholar
• Coleman CI, Baker WL, Kluger J, et al. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008;26:622-9
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011;12:65-82
   PubMed Web of Science ®Google Scholar
• Black HR, Elliott WJ, Grandits G, et al.; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000;18:1671-5
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010;33:1997-2003
   PubMed Web of Science ®Google Scholar
• Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization–International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999;21:1009-60
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
   PubMed Web of Science ®Google Scholar
• Miller AB, Reichek N, St John Sutton M, et al. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens 2010;4:302-10
   PubMed Web of Science ®Google Scholar
• NCT00744237. Available at: http://clinicaltrials.gov/ct2/show/NCT00744237 [Last accessed 6 June 2012]
   Google Scholar
• Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-8
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents JAMA 1982;248:2004-11
   Google Scholar
• Suwelack B, Kobelt V, Erfmann M, et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 2003;16:313-20
   PubMed Web of Science ®Google Scholar
• Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986;293:1145-51
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlöf B, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10
   PubMed Web of Science ®Google Scholar
• Gupta AK, Dahlof B, Dobson J, et al.; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-8
   PubMed Web of Science ®Google Scholar
• Nadim MK, Dua R, Campese VM. Antihypertensive drugs and the kidney. Curr Cardiol Rep 2004;6:403-8
   PubMedGoogle Scholar
• Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51
   PubMed Web of Science ®Google Scholar
• Ungar A, Di Serio C, Lambertucci L, et al. Calcium channel blockers and nephroprotection. Aging Clin Exp Res 2005;17(4 Suppl):31-9
   PubMedGoogle Scholar
• Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65(Suppl 2):29-39
   PubMedGoogle Scholar
• Monami M, Colombi C, Balzi D, et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011;34:129-31
   PubMed Web of Science ®Google Scholar
• Shang ZJ, Liu K, Liang de F. Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 2009;38:371-6
   PubMed Web of Science ®Google Scholar
• Pearce PC, Hawkey CM, Symons C, et al. The importance of membrane stabilization in protecting the developing rat myocardium from the actions of triac. Am J Cardiovasc Pathol 1988;2:173-9
   PubMedGoogle Scholar
• Mansuy P, Mougenot N, Ramirez-Gil JF, et al. Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. J Cardiovasc Pharmacol 2000;35:806-13
   PubMed Web of Science ®Google Scholar
• Fitzgerald PJ. Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin Epidemiol 2010;2:1-3
   PubMedGoogle Scholar
• Shan T, Ma Q, Zhang D, et al. β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol 2011;665:1-7
   PubMed Web of Science ®Google Scholar
• Wolter NE, Wolter JK, Enepekides DJ, et al. Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma. J Otolaryngol Head Neck Surg 2012;41:334-44
   PubMed Web of Science ®Google Scholar
• Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011;2:797-809
   PubMed Web of Science ®Google Scholar
• Beta-adrenergic blockers and breast cancer. Med Lett Drugs Ther 2012;54:6-7
   Google Scholar
• Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51
   PubMed Web of Science ®Google Scholar
• Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci 2011;52:155-70
   PubMed Web of Science ®Google Scholar
• Martini D, Monte MD, Ristori C, et al. Antiangiogenic effects of β(2) -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem 2011;119:1317-29
   PubMed Web of Science ®Google Scholar
• Filippi L, Cavallaro G, Fiorini P, et al. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr 2010;10:83
   PubMed Web of Science ®Google Scholar